Overview
Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow resistance in the diseased lung, leading to decreased cardiovascular workload in an attempt to oxygenate the lungs. Oxygen therapy is used to treat emphysema, pneumonia, some heart disorders (congestive heart failure), some disorders that cause increased pulmonary artery pressure, and any disease that impairs the body's ability to take up and use gaseous oxygen. Higher level of oxygen than ambient air (hyperoxia) can be introduced under normobaric or hyperbaric conditions.
Indication
Oxygen therapy in clinical settings is used across diverse specialties, including various types of anoxia, hypoxia or dyspnea and any other disease states and conditions that reduce the efficiency of gas exchange and oxygen consumption such as respiratory illnesses, trauma, poisonings and drug overdoses. Oxygen therapy tries to achieve hyperoxia to reduce the extent of hypoxia-induced tissue damage and malfunction.
Associated Conditions
- Anemia
- Cancer
- Hypoxemia
- Hypoxia
- Migraine
- Polycythemia
- Pulmonary Hypertension (PH)
- Respiratory Disorders
- Sleep Apnea
Research Report
Oxygen (DB09140): A Comprehensive Monograph on its Chemistry, Pharmacology, and Clinical Application
Section I: Introduction and Historical Context: From "Dephlogisticated Air" to Essential Medicine
Oxygen, the most abundant element in the Earth's crust, occupies a unique and paradoxical position within the modern pharmacopeia. It is simultaneously a fundamental component of the atmosphere essential for all aerobic life and a potent, regulated prescription drug with a defined therapeutic window and significant potential for toxicity. This dual identity—as both a life-sustaining substrate and a powerful therapeutic agent—frames the central challenge of its clinical application: the judicious use of a substance that can be life-saving when correcting hypoxia but life-threatening when administered in excess. The journey of oxygen from an unknown component of air to a cornerstone of medical therapy is a story of scientific revolution, contested discovery, and evolving understanding that mirrors the maturation of chemistry and medicine itself. This report provides a comprehensive monograph on oxygen (DrugBank ID: DB09140), detailing its history, physicochemical properties, complex pharmacology, diverse clinical applications, methods of administration, safety profile, and the unique regulatory framework that governs its use.
The scientific understanding of oxygen emerged from an intellectual landscape dominated by the phlogiston theory. In the 18th century, this theory posited that all combustible materials contained a fire-like element called "phlogiston," which was released during burning. What we now call oxidation was then understood as the release of phlogiston, and the remaining ash or calx was considered "dephlogisticated". It was within this paradigm that the first investigations into the nature of air and combustion took place, setting the stage for one of chemistry's most pivotal discoveries.[1]
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2021/01/11 | Not Applicable | Active, not recruiting | Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan | ||
2020/12/31 | Phase 2 | UNKNOWN | Ole Hyldegaard | ||
2020/10/22 | Phase 3 | UNKNOWN | |||
2020/09/25 | Not Applicable | Completed | Parc de Salut Mar | ||
2020/09/21 | Phase 3 | Completed | |||
2020/09/18 | N/A | Active, not recruiting | Kuopio University Hospital | ||
2020/09/07 | N/A | UNKNOWN | University Hospital Bispebjerg and Frederiksberg | ||
2020/08/05 | Phase 2 | UNKNOWN | |||
2020/06/11 | Not Applicable | Completed | |||
2020/05/28 | Phase 1 | Completed | Poznan University of Medical Sciences |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
C&C Oxygen Company | 50322-005 | RESPIRATORY (INHALATION) | 990 mL in 1 L | 10/18/2023 | |
Jenco Medical and Mobility, Inc | 66988-100 | RESPIRATORY (INHALATION) | 1 L in 1 L | 6/14/2010 | |
Roberts Oxygen Company, Inc. | 46123-121 | RESPIRATORY (INHALATION) | 900 mL in 1 L | 11/19/2020 | |
Riverside Health Equipment | 66966-0001 | RESPIRATORY (INHALATION) | 99 L in 100 L | 12/23/2009 | |
Medassure Inc | 62914-1000 | RESPIRATORY (INHALATION) | 99 L in 100 L | 10/3/2023 | |
Medical-Technical Gases, Inc. | 10736-009 | RESPIRATORY (INHALATION) | 95 mL in 1 L | 12/22/2012 | |
Homeside Healthcare, Inc. | 24319-0001 | RESPIRATORY (INHALATION) | 99 L in 100 L | 12/17/2009 | |
Medical-Technical Gases, Inc. | 10736-010 | RESPIRATORY (INHALATION) | 95 mL in 1 L | 12/22/2012 | |
Industrial Welding & Tool Supply, Ltd. | 58404-001 | RESPIRATORY (INHALATION) | 995 mL in 1 L | 10/18/2023 | |
Diamond Drugs Inc. dba Diamond Medical Supply | 55322-0001 | RESPIRATORY (INHALATION) | 99 L in 100 L | 10/13/2023 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
View More Health Canada Approvals
Sign in to access additional Health Canada approved drug information with detailed regulatory data.
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
LUNG DIFFUSION TEST MIXTURE | matheson gas products canada inc. | 00580767 | Gas - Inhalation | 23 % | 12/31/1982 |
OXYGEN USP | ontario home oxygen and respiratory service inc. | 02242542 | Gas - Inhalation | 99 % | 7/13/2000 |
OXYGEN USP | liquid carbonic inc. | 00684635 | Gas - Inhalation | 99 % | 12/31/1968 |
ALNOX GAS | Air Liquide Canada Inc. | 02071010 | Gas - Inhalation | 50 % | 12/31/1995 |
MEDICAL AIR U.S.P. | 02154781 | Gas - Inhalation | 23.5 % / V/V | 12/31/1995 | |
OXYGEN USP, HELIUM USP, MEDICAL GAS MIXTURE | Praxair Canada Inc | 02014440 | Gas - Inhalation | 24 % | 12/31/1993 |
OXYGEN 99.95% | south-western ontario welding suppl ltd. | 00865044 | Gas - Inhalation | 99.95 % | 12/31/1991 |
OXYGEN | respiratory homecare solutions canada inc. | 02248123 | Gas - Inhalation | 99 % | 11/1/2003 |
OXYGEN COMPRESSED U.S.P. | messer canada | 02171457 | Gas - Inhalation | 99.5 % | 12/31/1991 |
LUNG DIFFUSION TEST MIX NO NE CO | Praxair Canada Inc | 00588075 | Gas - Inhalation | 21 % | 12/30/1970 |
CIMA AEMPS Drug Approvals
View More CIMA AEMPS Approvals
Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
View More Philippines FDA Approvals
Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
View More Saudi SFDA Approvals
Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
View More Malaysia NPRA Approvals
Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
View More UK EMC Drug Information
Sign in to access additional UK EMC drug information with detailed pharmaceutical data.
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.